Back to Search
Start Over
Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women
- Source :
- Current Vascular Pharmacology. 9:647-657
- Publication Year :
- 2011
- Publisher :
- Bentham Science Publishers Ltd., 2011.
-
Abstract
- AIM: To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. PATIENTS-METHODS: This prospective, randomized, target driven study included 1,123 subjects (512/611 men/women, aged 45-65 years) with metabolic syndrome (MetS) without diabetes or CVD referred to specialist outpatient clinics. Patients were randomized to two treatment groups: group A with low density lipoprotein cholesterol (LDL-C) target of < 100 mg/dl and group B with a target of < 130 mg/dl. Atorvastatin was used in both groups on top of optimal multifactorial treatment, (quinapril, amlodipine, hydrochlorothiazide for hypertension, metformin for impaired fasting glucose, and orlistat for obesity). The e-CVD risk was calculated using the Framingham, the PROCAM and Reynold's equations. RESULTS: Reductions in e-CVD risk at 6 months were > 50%in all patients, but were superior in group A and in women. Reductions were even greater during the next 3-years and were mainly attributed to changes in lipid profile. Actual CVD events were 1 in group A and 13 in group B; p=0.0012. CONCLUSIONS: Attaining the treatment target of LDL-C < 100 mg/dl within multifactorial treatment of MetS by expert clinics, is achievable and beneficial even in patients without diabetes or known CVD. This induces a considerable e-CVD risk reduction in MetS patients. Actual CVD events were negligible, suggesting that e-CVD risk overestimates actual CVD risk in MetS, at least in patients achieving LDL-C < 100 mg/dl [ClinicalTrials.gov ID: NCT00416741]. Curr Vasc Pharmacol
- Subjects :
- Male
medicine.medical_specialty
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
Atorvastatin
Disease
Group B
law.invention
Treatment and control groups
Sex Factors
Randomized controlled trial
Risk Factors
law
Cholesterol, LDL/blood/*drug effects
Diabetes mellitus
Internal medicine
Humans
Medicine
Outpatient clinic
Pyrroles
Treatment effect
Prospective Studies
Prospective cohort study
Aged
Metabolic Syndrome
Pharmacology
medicine.diagnostic_test
business.industry
Pyrroles/*therapeutic use
Cholesterol, LDL
Middle Aged
medicine.disease
Heptanoic Acids/*therapeutic use
Metabolic Syndrome X/complications/*drug therapy
Cardiovascular Diseases
Heptanoic Acids
Cardiovascular Diseases/etiology/*prevention & control
Physical therapy
Female
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Metabolic syndrome
Cardiology and Cardiovascular Medicine
business
Lipid profile
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 15701611
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Current Vascular Pharmacology
- Accession number :
- edsair.doi.dedup.....886d66cda30aa2c0ff01df268244bfd9